(Q46228962)

20 December 2017

title

Database of somatic mutations in EGFR with analyses revealing indel hotspots but no smoking-associated signature (English)

1 reference

20 December 2017

0 references

Dongqing Gu

1

1 reference

20 December 2017

William A Scaringe

2

1 reference

20 December 2017

Kai Li

3

1 reference

20 December 2017

Juan-Sebastian Saldivar

4

1 reference

20 December 2017

Kathleen A Hill

5

1 reference

20 December 2017

Zhenbin Chen

6

1 reference

20 December 2017

Kelly D Gonzalez

7

1 reference

20 December 2017

Steve S Sommer

8

1 reference

20 December 2017

publication date

1 August 2007

1 reference

20 December 2017

published in

Human Mutation

1 reference

20 December 2017

volume

28

1 reference

20 December 2017

issue

8

1 reference

20 December 2017

page(s)

760-770

1 reference

20 December 2017

Evidence that proximal multiple mutations in Big Blue transgenic mice are dependent events

cites work

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.20512

The Big Blue(R) transgenic mouse mutation detection assay: the mutation pattern of sectored mutant plaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.20512

Spontaneous tandem-base mutations (TBM) show dramatic tissue, age, pattern and spectrum specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.20512

Spontaneous multiple mutations show both proximal spacing consistent with chronocoordinate events and alterations with p53-deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.20512

Human germline mutation in the factor IX gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.20512

High epidermal growth factor receptor amplification rate but low mutation frequency in Middle East lung cancer population

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.20512

7 January 2021

Tandem-base mutations occur in mouse liver and adipose tissue preferentially as G:C to T:A transversions and accumulate with age.

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.20512

7 January 2021

Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.20512

7 January 2021

Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.20512

7 January 2021

Distinctive activation patterns in constitutively active and gefitinib-sensitive EGFR mutants

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.20512

7 January 2021

Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.20512

7 January 2021

Meta-analysis of indels causing human genetic disease: mechanisms of mutagenesis and the role of local DNA sequence complexity

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.20512

7 January 2021

The CpG dinucleotide and human genetic disease

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.20512

7 January 2021

Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients.

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.20512

7 January 2021

Pharmacogenomics. Cancer sharpshooters rely on DNA tests for a better aim.

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.20512

7 January 2021

Significance of EGFR protein expression and gene amplification in non-small cell lung carcinoma.

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.20512

7 January 2021

Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.20512

7 January 2021

Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.20512

7 January 2021

ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.20512

7 January 2021

Sensitivity of non-small-cell lung cancer cell lines established from patients treated with prolonged infusions of Paclitaxel

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.20512

7 January 2021

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.20512

7 January 2021

Mutations and addiction to EGFR: the Achilles 'heal' of lung cancers?

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.20512

7 January 2021

Somatic microindels: analysis in mouse soma and comparison with the human germline

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.20512

7 January 2021

Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.20512

7 January 2021

Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.20512

7 January 2021

The molecular epidemiology of p53 gene mutations in human breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.20512

7 January 2021

Preferential occurrence of 1-2 microindels

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.20512

7 January 2021

High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.20512

7 January 2021

Epidermal growth factor receptor mutations in patients with non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.20512

7 January 2021

Predictors of the response to gefitinib in refractory non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.20512

7 January 2021

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.20512

7 January 2021

Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications.

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.20512

7 January 2021

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.20512

7 January 2021

EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.20512

7 January 2021

Reporting results of cancer treatment

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.20512

7 January 2021

Gefitinib-sensitive mutations of the epidermal growth factor receptor tyrosine kinase domain in chinese patients with non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.20512

7 January 2021

Toxicity and response criteria of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.20512

7 January 2021

The IARC TP53 database: new online mutation analysis and recommendations to users

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.20512

7 January 2021

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.20512

7 January 2021

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.20512

7 January 2021

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.20512

7 January 2021

Global cancer statistics, 2002

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.20512

7 January 2021

EGFR Mutation status in Japanese lung cancer patients: genotyping analysis using LightCycler

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.20512

7 January 2021

Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.20512

7 January 2021

Recent human germ-line mutation: inferences from patients with hemophilia B.

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.20512

7 January 2021

Mutations in the epidermal growth factor receptor gene are linked to smoking-independent, lung adenocarcinoma

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.20512

7 January 2021

Mutational analysis of EGFR and K-RAS genes in lung adenocarcinomas.

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.20512

7 January 2021

Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.20512

7 January 2021

Human Gene Mutation Database (HGMD): 2003 update

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.20512

7 January 2021

Epidermal growth factor receptor expression status in lung cancer correlates with its mutation

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.20512

7 January 2021

Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.20512

7 January 2021

Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas.

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.20512

7 January 2021

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.20512

7 January 2021

Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255.

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.20512

7 January 2021

Erlotinib in lung cancer - molecular and clinical predictors of outcome

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.20512

7 January 2021

Mutations in the tyrosine kinase domain of the epidermal growth factor receptor in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.20512

7 January 2021

The EGFR mutation and its correlation with response of gefitinib in previously treated Chinese patients with advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FHUMU.20512

7 January 2021

Identifiers

DOI

10.1002/HUMU.20512

1 reference

20 December 2017

release_vnjhhdv34rhkhedwpwmhyneav4

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/vnjhhdv34rhkhedwpwmhyneav4

24 November 2022

mapped directly with Wikidata item

1 reference

20 December 2017